Promethazine with Codeine Should NOT Be Prescribed to Adolescents
Do not prescribe promethazine with codeine (Phenergan with Codeine) to adolescents aged 12-18 years. The FDA explicitly warns against using codeine in this age group, particularly for adolescents who are obese or have conditions that increase respiratory risk such as obstructive sleep apnea or severe lung disease 1. This recommendation is based on serious safety concerns regarding respiratory depression and death.
FDA Contraindications and Warnings
The regulatory framework is clear and unambiguous:
- Codeine is contraindicated for treating pain or cough in children under 12 years 1
- Codeine is contraindicated after tonsillectomy/adenoidectomy in anyone under 18 years 1
- The FDA specifically warns against codeine use in adolescents 12-18 years who have obesity or respiratory conditions that increase breathing problem risk 1
The FDA issued multiple safety warnings starting in 2012 regarding respiratory depression in rapid metabolizers, followed by a 2013 restriction for post-surgical use in those under 18, and continued warnings in 2015 1.
Promethazine-Specific Concerns in Adolescents
Promethazine itself carries significant risks in younger patients:
- Respiratory depression is a major concern, with postmarketing reports of fatalities in pediatric patients 2
- Antiemetics should not be used in vomiting of unknown etiology in children and adolescents 2
- The combination of promethazine with codeine creates additive respiratory depressant effects that should be avoided 2
Clinical Reasoning
The 2021 JAMA Surgery expert panel guidelines on opioid prescribing in children and adolescents after surgery explicitly endorse FDA guidelines regarding limited use of codeine and tramadol for children younger than 18 years 1. This represents the most recent high-quality guidance available.
The mechanism of concern involves codeine's metabolism via CYP2D6 to morphine. Rapid metabolizers convert codeine to morphine more quickly, leading to dangerously high morphine levels and potentially fatal respiratory depression. This genetic variability cannot be predicted before prescribing, making the drug inherently unsafe in pediatric populations.
Safer Alternatives
For adolescents requiring analgesia or cough suppression:
- For pain: Use acetaminophen, NSAIDs, or if opioids are absolutely necessary, consider alternatives like oxycodone or hydrocodone (though these also require careful consideration)
- For cough: Use non-opioid antitussives like dextromethorphan
- For nausea: Use ondansetron or other antiemetics without respiratory depressant effects
The guideline emphasizes opioid-sparing multimodal analgesia approaches including regional anesthesia, acetaminophen, NSAIDs, and dexamethasone 1.
Critical Pitfall to Avoid
Do not be swayed by historical prescribing patterns or patient/parent requests for "purple drank" formulations. The recreational misuse of promethazine-codeine combinations has been well-documented 3, 4, and the combination poses both addiction risk and acute toxicity risk in adolescents.